A Randomized, Double-masked, Multicenter,Sham-controlled, Safety and Efficacy Study of KH902 in Patients With Wet AMD

Exclusion Criteria

• •Current or previous non-exudative AMD diseases which affect the inspection and measurement of macular or the central visual acuity;
• •Subretinal hemorrhage area≥ 50% of total lesion size;
• •Scar or fibrosis area in study eyes ≥ 50% of total lesion size; or central foveal scar、fibrosis or atrophy of macular in the study eye;
• •Presence of retinal pigment epithelial tear, retinal macular tractional, macular epiretinal membrane, and diagnosed with polypoidal choroidal vasculopathy in the study eye;
• •Previous anti-VEGF drug treatment in the study eye within six months preceding screening; or anti-VEGF treatment in the fellow eye within three months before screening;
• •Previous intraocular or periocular operations, excluding operations on eyelid without hampering the intravitreal injection in the study eye;
• •Previous ophthalmologic operations in the study eye;
• •Current active inflammation or infection in either eye;
• •Uncontrolled previous or current glaucoma in either eye, or previous glaucoma filtering operation in the study eye;
• •Current systemic administrations which may lead to toxicity in the crystalline lens;
• •History of allergy or current allergic response;
• •History of surgery within one month preceding enrollment;
• •Infectious diseases need systemic administration;
• •Systemic autoimmune diseases;
• •Any uncontrolled clinical disorders;
• •Patients of child-bearing potential do not adopted adequate contraception methods;
• •Pregnant or nursing women;
• •Patients should be excluded in the opinion of investigators;